ATH 1019
Alternative Names: ATH-1019Latest Information Update: 23 May 2022
Price :
$50 *
At a glance
- Originator Athira Pharma
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders; Psychiatric disorders